JP2005532373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532373A5 JP2005532373A5 JP2004518221A JP2004518221A JP2005532373A5 JP 2005532373 A5 JP2005532373 A5 JP 2005532373A5 JP 2004518221 A JP2004518221 A JP 2004518221A JP 2004518221 A JP2004518221 A JP 2004518221A JP 2005532373 A5 JP2005532373 A5 JP 2005532373A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- hyaluronan
- composition according
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003993 interaction Effects 0.000 claims description 8
- 150000002016 disaccharides Chemical class 0.000 claims description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 238000000034 method Methods 0.000 claims 24
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 23
- 229920002674 hyaluronan Polymers 0.000 claims 23
- 229940099552 hyaluronan Drugs 0.000 claims 23
- 239000003814 drug Substances 0.000 claims 17
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 230000005855 radiation Effects 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 230000001093 anti-cancer Effects 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- 108010013214 Hyaluronan Receptors Proteins 0.000 claims 4
- 102000018866 Hyaluronan Receptors Human genes 0.000 claims 4
- 229960002949 fluorouracil Drugs 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 230000026731 phosphorylation Effects 0.000 claims 3
- 238000006366 phosphorylation reaction Methods 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 229940009456 adriamycin Drugs 0.000 claims 2
- 238000003782 apoptosis assay Methods 0.000 claims 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 2
- 229940088954 camptosar Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 230000005757 colony formation Effects 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229940080856 gleevec Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 230000036457 multidrug resistance Effects 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims 2
- 230000005522 programmed cell death Effects 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229940099039 velcade Drugs 0.000 claims 2
- 229960001722 verapamil Drugs 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102000011727 Caspases Human genes 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102100035427 Forkhead box protein O1 Human genes 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000877727 Homo sapiens Forkhead box protein O1 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- -1 S-9788 Chemical compound 0.000 claims 1
- YJDYDFNKCBANTM-QCWCSKBGSA-N SDZ PSC 833 Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000002929 anti-fatigue Effects 0.000 claims 1
- 239000003173 antianemic agent Substances 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 150000001718 carbodiimides Chemical class 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 108010019594 cyclosporin D Proteins 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000000913 erythropoietic effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 108010003425 hyaluronan-mediated motility receptor Proteins 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- OKPYIWASQZGASP-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(O)CNC(=O)C(C)=C OKPYIWASQZGASP-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical class O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims 1
- 229960002324 trifluoperazine Drugs 0.000 claims 1
- 108010082372 valspodar Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 2
- 102100021407 ATP-dependent RNA helicase DDX18 Human genes 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 101150027313 Has2 gene Proteins 0.000 description 1
- 101001041703 Homo sapiens ATP-dependent RNA helicase DDX18 Proteins 0.000 description 1
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 1
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39290502P | 2002-07-01 | 2002-07-01 | |
| US60/392,905 | 2002-07-01 | ||
| US45376103P | 2003-03-11 | 2003-03-11 | |
| US60/453,761 | 2003-03-11 | ||
| PCT/US2003/020918 WO2004003545A1 (en) | 2002-07-01 | 2003-07-01 | Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010013291A Division JP2010116410A (ja) | 2002-07-01 | 2010-01-25 | ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005532373A JP2005532373A (ja) | 2005-10-27 |
| JP2005532373A5 true JP2005532373A5 (enExample) | 2010-03-18 |
| JP5027387B2 JP5027387B2 (ja) | 2012-09-19 |
Family
ID=30003285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004518221A Expired - Fee Related JP5027387B2 (ja) | 2002-07-01 | 2003-07-01 | ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物 |
| JP2010013291A Pending JP2010116410A (ja) | 2002-07-01 | 2010-01-25 | ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010013291A Pending JP2010116410A (ja) | 2002-07-01 | 2010-01-25 | ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8093217B2 (enExample) |
| EP (2) | EP2434282A3 (enExample) |
| JP (2) | JP5027387B2 (enExample) |
| AU (1) | AU2003280471B2 (enExample) |
| CA (1) | CA2513143A1 (enExample) |
| WO (1) | WO2004003545A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2434282A3 (en) | 2002-07-01 | 2012-08-22 | Tufts University | Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| WO2006033693A2 (en) * | 2004-06-30 | 2006-03-30 | Deangelis Paul L | Methods of selectively treating diseases with specific glycosaminoglycan polymers |
| WO2006128041A2 (en) * | 2005-05-26 | 2006-11-30 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of chemoresistant neoplasia |
| EP2690178B1 (en) * | 2006-10-03 | 2021-12-22 | The Board Of Regents Of The University Of Oklahoma | Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| EP2567975A3 (en) * | 2006-11-21 | 2013-07-03 | The Regents of The University of California | Modulation of RHAMM (CD168) for selective adipose tissue development |
| US20100062000A1 (en) * | 2006-11-21 | 2010-03-11 | The Regents Of The University Of California | Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations |
| EP2307571A4 (en) * | 2008-06-26 | 2012-03-07 | Univ South Florida | PROOF AND SENSITIZATION PROCEDURE FOR THE PLATINUM RESISTANCE OF CANCER DISORDERS |
| CA2703532C (en) * | 2010-05-10 | 2018-05-01 | Eva Turley | Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications |
| RU2015123315A (ru) | 2012-11-25 | 2017-01-10 | Зе Реджентс Оф Зе Юниверсити Оф Калифорния | Пептиды, стимулирующие подкожный адипогенез |
| CA2928568A1 (en) * | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| WO2015184125A1 (en) | 2014-05-28 | 2015-12-03 | The Regents Of The University Of California | Peptides, compositions, and methods for stimulating subcutaneous adipogenesis |
| EP3271383A4 (en) | 2015-03-20 | 2019-06-12 | London Health Sciences Centre Research Inc. | GASED PEPTIDES AND USES THEREOF |
| CA3023980A1 (en) | 2016-05-16 | 2017-11-23 | Checkmab S.R.L. | Markers selectively deregulated in tumor-infiltrating regulatory t cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2850376B2 (ja) * | 1988-08-02 | 1999-01-27 | 日産化学工業株式会社 | 抗癌剤薬効増強剤 |
| CA2122519C (en) * | 1994-04-29 | 2001-02-20 | Rudolf Edgar Dr. Falk | Cancer treatment and metastasis prevention |
| US5902795A (en) * | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
| AU4071197A (en) * | 1996-08-16 | 1998-03-06 | Yale University | Phenotypic conversion of drug-resistant bacteria to drug-sensitivity |
| EP1087785A2 (en) * | 1998-06-15 | 2001-04-04 | Arch Development Corporation | Combination of radiotherapy and anti-angiogenic factors |
| HK1041209A1 (zh) | 1999-01-13 | 2002-07-05 | Meditech Research Limited | 加強藥物療效的成份及方法 |
| US6593308B2 (en) * | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
| JP2004505890A (ja) * | 2000-04-04 | 2004-02-26 | ノバルティス アクチエンゲゼルシャフト | 抗新生物剤に耐性の細胞を処置する方法 |
| US7534772B2 (en) * | 2000-06-22 | 2009-05-19 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
| AUPQ879500A0 (en) * | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
| EP2434282A3 (en) | 2002-07-01 | 2012-08-22 | Tufts University | Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
-
2003
- 2003-07-01 EP EP11179892A patent/EP2434282A3/en not_active Withdrawn
- 2003-07-01 EP EP03742415A patent/EP1532434A4/en not_active Withdrawn
- 2003-07-01 WO PCT/US2003/020918 patent/WO2004003545A1/en not_active Ceased
- 2003-07-01 AU AU2003280471A patent/AU2003280471B2/en not_active Ceased
- 2003-07-01 CA CA002513143A patent/CA2513143A1/en not_active Abandoned
- 2003-07-01 JP JP2004518221A patent/JP5027387B2/ja not_active Expired - Fee Related
-
2004
- 2004-04-29 US US10/835,511 patent/US8093217B2/en not_active Expired - Fee Related
-
2010
- 2010-01-25 JP JP2010013291A patent/JP2010116410A/ja active Pending
-
2011
- 2011-12-28 US US13/338,809 patent/US8648047B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532373A5 (enExample) | ||
| JP5688288B2 (ja) | がんの処置のための相乗的な医薬の組合せ | |
| TWI222863B (en) | Synergistic pharmaceutical compositions comprising anthracycline derivatives and anticancer agents | |
| Haura | Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies | |
| Maier et al. | New approaches in targeted therapy for medulloblastoma in children | |
| US20220259254A1 (en) | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy | |
| US11730836B2 (en) | Synergistic cancer treatment | |
| US20210353670A1 (en) | Nanoparticles for use as a therapeutic vaccine | |
| Shen et al. | Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: a mini-review | |
| US20220105114A1 (en) | Methods for treating chemoresistant cancer-initiating cells | |
| JP2010528091A (ja) | ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法 | |
| CN109498627A (zh) | 一种治疗肿瘤的药物组合物及其应用 | |
| Li et al. | The mTOR kinase inhibitor CZ415 inhibits human papillary thyroid carcinoma cell growth | |
| CN113329772B (zh) | 化学疗法与重组齐整小核菌凝集素的联合疗法 | |
| US11541061B2 (en) | Neuroblastoma treatment with taurolidine hydrolysis products | |
| Zhang et al. | A syringeable immunotherapeutic hydrogel enhances T cell immunity via in-situ activation of STING pathway for advanced breast cancer postoperative therapy | |
| CN114126660A (zh) | 药物复合物及其制备方法和用途 | |
| Kosianova et al. | Clofazimine enhances anti-glioma effect of immunotherapy | |
| CN101795728A (zh) | 用于治疗癌症的异噁唑化合物 | |
| Sethi et al. | Ipid nanomedicine simultaneously inhibits BRD4/PI3K and MDM2/XIAP signaling pathways for effective treatment of Medulloblastoma | |
| CN1204894C (zh) | 2－甲氧基雌二醇，硫酸新霉素及其混合物的抗癌用途 | |
| Ruff et al. | Exth-32. Development of EphA3 directed chimeric antigen receptor T cell therapy for the treatment of glioblastoma multiforme | |
| CN112569240A (zh) | 盐酸氯丙嗪在制备细胞周期素蛋白抑制剂中的用途 | |
| Samec et al. | –DIV3W PEPTIDE-MEDIATED DELIVERY OF siRNAS TARGETING CSNK2A1 INTO OVARAIN CANCER CELLS IN VIVO | |
| 정성우 | Design and development of multi-targeted anticancer agents for anti-angiogenic therapy or tumor tissue-selective delivery |